BIOPRENEURS BITES from California Takshila University
BIOPRENEURS BITES from California Takshila University
********************************************************************************
-----------------------------------------------------------------------------------
Global Health Progress Joins WHO and DNDi to Call For Increased Commitments to Fighting Neglected Tropical Diseases
The worldwide pharmaceutical industry is joining the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) in calling on the G-8 nations the importance of neglected diseases as a global health threat and a major strain on the economic viability and educational development of communities worldwide.
The newly formed Alliance urged G-8 to finance successful treatment and prevention programs, to support innovative strategies that address the challenging health gaps in developing countries, and to fund research and development to develop improved diagnostic, treatment and prevention options.
Most international attention is focused on HIV/AIDS, tuberculosis, malaria and global health security. However, neglected tropical diseases - most of which are preventable and treatable - remain major causes of death and disability worldwide. These diseases receive less funding and less attention while they decrease productivity, negatively affect quality of life and increase poverty throughout the developing world.
*********************************************************************************
India's Hepatitis B Virus Drug Market Will Grow Ten-Fold by 2012
*********************************************************************************
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Indian hepatitis B virus drug market will grow ten-fold by 2012, from $1.7 million in 2007 to $17 million in 2012. According to the new Emerging Markets report entitled Hepatitis B Virus in India, this growth will be fueled by a growing awareness of the hepatitis B virus and the growth of individual wealth among India's urban middle and upper class.
Additionally, the report finds that the number of prevalent cases of chronic hepatitis B virus in India (30.6 million in 2007) is three times that of the United States, France, Germany, Italy, Spain, United Kingdom and Japan combined. However, both diagnosis rates and drug treatment rates in India are extremely low.
**********************************************************************************
China's Hepatitis B Virus Drug Market Will Grow to $800 Million by 2012
*****************************************************************************************
Decision Resources also finds that the Chinese hepatitis B virus drug market will more than double by 2012, from $340 million in 2007 to $800 million in 2012. Both nucleoside/nucleotide analogues (NAs) and immunomodulators will experience strong double-digit growth, contributing to a robust 18 percent annual growth of the total market.
According to the new Emerging Markets report entitled Hepatitis B Virus in China, the greatest contributor to the growth of the Chinese hepatitis B drug market is the sheer size and nature of the epidemic in China- approximately 80 million Chinese people have chronic hepatitis B. Because treatment with nucleoside/nucleotide analogues is typically long-term (in many cases, lifelong), even steady diagnosis and drug-treatment rates would generate sizable near-term growth in this market. Government-sponsored improvements to the healthcare system and increasing economic prosperity among the Chinese population have also added to this market growth.
BIOPRENEURS BITES from California Takshila University - To learn more about this author, visit Ryan Baidya's Website.
Like this article? Share it with your friends
One billion people suffer from preventable, treatable diseases around the world
********************************************************************************
-----------------------------------------------------------------------------------
Global Health Progress Joins WHO and DNDi to Call For Increased Commitments to Fighting Neglected Tropical Diseases
The worldwide pharmaceutical industry is joining the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) in calling on the G-8 nations the importance of neglected diseases as a global health threat and a major strain on the economic viability and educational development of communities worldwide.
The newly formed Alliance urged G-8 to finance successful treatment and prevention programs, to support innovative strategies that address the challenging health gaps in developing countries, and to fund research and development to develop improved diagnostic, treatment and prevention options.
Most international attention is focused on HIV/AIDS, tuberculosis, malaria and global health security. However, neglected tropical diseases - most of which are preventable and treatable - remain major causes of death and disability worldwide. These diseases receive less funding and less attention while they decrease productivity, negatively affect quality of life and increase poverty throughout the developing world.
*********************************************************************************
India's Hepatitis B Virus Drug Market Will Grow Ten-Fold by 2012
*********************************************************************************
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Indian hepatitis B virus drug market will grow ten-fold by 2012, from $1.7 million in 2007 to $17 million in 2012. According to the new Emerging Markets report entitled Hepatitis B Virus in India, this growth will be fueled by a growing awareness of the hepatitis B virus and the growth of individual wealth among India's urban middle and upper class.
Additionally, the report finds that the number of prevalent cases of chronic hepatitis B virus in India (30.6 million in 2007) is three times that of the United States, France, Germany, Italy, Spain, United Kingdom and Japan combined. However, both diagnosis rates and drug treatment rates in India are extremely low.
**********************************************************************************
China's Hepatitis B Virus Drug Market Will Grow to $800 Million by 2012
*****************************************************************************************
Decision Resources also finds that the Chinese hepatitis B virus drug market will more than double by 2012, from $340 million in 2007 to $800 million in 2012. Both nucleoside/nucleotide analogues (NAs) and immunomodulators will experience strong double-digit growth, contributing to a robust 18 percent annual growth of the total market.
According to the new Emerging Markets report entitled Hepatitis B Virus in China, the greatest contributor to the growth of the Chinese hepatitis B drug market is the sheer size and nature of the epidemic in China- approximately 80 million Chinese people have chronic hepatitis B. Because treatment with nucleoside/nucleotide analogues is typically long-term (in many cases, lifelong), even steady diagnosis and drug-treatment rates would generate sizable near-term growth in this market. Government-sponsored improvements to the healthcare system and increasing economic prosperity among the Chinese population have also added to this market growth.
BIOPRENEURS BITES from California Takshila University - To learn more about this author, visit Ryan Baidya's Website.
Like this article? Share it with your friends
 | |
 |
No article feedback found. |
| |
Leave Your Feedback |
 | |
| |||
David BarrDavid Barr is the President of Venture Opportunities, Inc. David has been a professional business broker/intermediary since 1980 focusing on General Business Brokerage and Mergers and Acquisitions representing client transaction value from $400,000 to $20,000,000. Mr. Barr has handled the sale of over four hundred and fifty companies. David earned a university degree from the State University of New York majoring in economics and business. David holds the Mergers and Acquisition Master Intermediary and the Certified Business Intermediary designations from the International Business Brokers Association. He is also a Senior Business Analyst and a Texas licensed Real Estate Agent. For more information about David and Venture Opportunities, visit www.bizdealmaker.com. - Visit David Barr's Website |
|||
Stephanie RobeyStephanie Robey is President and CoFounder of Pivot Positive, LLC - an Internet marketing business focused on helping people start work at home ventures. Previously, she was employed at The Search Agency with over 20 years experience in graphic design and 10 years experience in online marketing. She was responsible for launching the Conversion Path Optimization (CPO) unit where she and her team have conducted hundreds of optimization tests for online companies across multiple verticals. She is a successful entrepreneur having started and sold 2 companies and remains on the board of directors of the third, PhotoSpin.com Stephanie began her career in the direct marketing realm creating and producing direct mail for many of the major cable television companies and directly attributes her understanding of Internet marketing to those early offline experiences. Stephanie is a graduate of San Diego State University with a BFA in Graphic Arts and also holds an Executive MBA from the Graziadio School of Business and Management at Pepperdine University. Read Steph's Blog Meet Steph and Dave Sign up for our Free 7-Day BootCamp: Self Employed & Rich - Visit Stephanie Robey's Website |
|||
John BrennanJohn Brennan Ed.D. Dr. Brennan is President of Interpersonal Development, LLC, a training and development firm. Interpersonal Development has provided sales training and coaching to more than 3,000 sales reps from over 100 companies. A native of Australia, Dr. Brennan received his doctorate from the University of Rochester. His dissertation researched the effectiveness of Behavioral Modeling Technology in training people in interpersonal skills. While he has spent most of his career designing or delivering training, he was also a Vice-President of Sales of a training and development franchise with operations in 25 markets. Dr. Brennan has designed and delivered sales training in North America, Asia, Europe, Australia and the Middle East. He has been a guest speaker at numerous national and regional professional conferences. When Microsoft wanted Best Practices articles on sales for their web site, they called Dr. Brennan. The results are at http://office.microsoft.com/en-us/FX011387391033.aspx His firm’s clients have included Volvo, The Prudential, Merrill Lynch, Eastman Kodak, Gannett, Equifax Europe, the Economist Group and countless small businesses. - Visit John Brennan's Website |
|||
Linda RichardsonLinda Richardson is the Founder and Executive Chairwoman of Richardson, a global sales training and performance improvement company. As a recognized leader in the industry, she has won the coveted Stevie Award for Lifetime Achievement in Sales Excellence and she was identified by Training Industry, Inc. as one of the “Top 20 Most Influential Training Professionals.” Ms. Richardson is credited with the movement to Consultative Selling and is the author of ten books on selling and sales management, including Sales Coaching — Making the Great Leap from Sales Manager to Sales Coach, and Stop Telling, Start Selling. She teaches sales and management at the Wharton Graduate School of the University of Pennsylvania and the Wharton Executive Development Center. Linda is a frequent speaker at industry and client conferences, has been published extensively in industry and training journals, and has been featured in numerous publications, including The Wall Street Journal, Forbes, Nation’s Business, Selling Power, Success, and The Conference Board Magazine. Learn more about Richardson's sales training and performance improvement solutions at http://www.richardson.com web - Visit Linda Richardson's Website |
|||
|
To learn more about the Evan Elite Author Program please contact us. | |||
 | |
|  |
Subscribe to Ryan's articles
 | |
|
|  |
 | |
|
| |
 | |||||||
|
 | ||
 |
||
|
||
|
||
|
| ||
 |
| Have you written articles that would be of value to entrepreneurs? Become an expert on our site by publishing them! Expose yourself to a wide audience, drive more traffic to your website and get more sales! Click Here for details. |
|
|
 |
| Modeling the Masters: Learn the true secrets behind Walt Disney's business success factors & grow your company! Video produced by Phanta Media |
|
|
 |
"Learn straight from Evan how you can Make a Full Time Income (And More) from a Website"
Click Here To Learn More |
|
|
|
|
Get advice & tips from famous business owners, new articles by entrepreneur experts, my latest website updates, & special sneak peaks at what's to come!
|
|
|
 Delegation Workbook Leadership Assessment EQ Coaching Report Salesperson Selection Winning Sales Letter |
|
 | ||
 |
Fortune Hunters
CBC Entrepreneur TV | |
 |
Choose A PR Topic
Press Release Builder | |
| ||
 | ||||
| ||||
|
| ||||
| ||||
|
|
|
|
|
||||||
|
Email us your ideas on how to make our website more valuable! Thank you Sharon from Toronto Salsa Lessons / Classes for your suggestions to make the newsletter look like the website and profile younger entrepreneurs like Jennifer Lopez and Sean Combs!
|
|
|
| ||||||||||
|
| ||||||||||
|
|
||||||||||